HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") $(TVRD)$, a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today reported its nancial and operating results for the third quarter ended September 30, 2026, and provided a business update.
Business and Clinical Program Updates:
TTI-109 -- Ulcerative Colitis (UC)
-- Advancing development plans for TTI-109 in UC. Building on positive Phase
1 healthy volunteer results reported in July and the subsequent selection
of UC as its initial target indication, Tvardi is preparing to advance
TTI-109 into clinical development in UC, subject to clearance of our
Investigational New Drug (IND) application and additional funding.
-- The Phase 1 results confirmed the prodrug design, with TTI-109
delivering TTI-101-equivalent exposure with improved tolerability
and, across the active dose range, demonstrated reductions in
cellular and humoral immune populations known to correlate with UC
disease severity, providing pharmacodynamic evidence of STAT3
target engagement.
-- Published additional preclinical data supporting STAT3 inhibition in UC.
New findings published in the International Journal of Molecular Sciences
demonstrated that, in a preclinical model of chronic colitis, TTI-101
achieved colon tissue exposure approximately eightfold higher than in
plasma, normalized disease-associated changes in colon gene expression,
muted colitis-associated changes in the gut microbiome and prevented the
formation of colon adenocarcinomas, a long-term consequence of chronic
colitis.
-- The preclinical data highlights the potential of STAT3 inhibition
to address immune dysregulation, inflammation and fibrosis that
drive UC progression. These findings build on prior preclinical
studies in which TTI-101 and TTI-109 significantly reduced disease
activity across three acute colitis models representing distinct
immune axes.
TTI-101 -- Hepatocellular Carcinoma $(HCC)$
-- Advancing Phase 1b/2 REVERT LIVER CANCER study toward topline readout in
early first quarter of 2027. The ongoing REVERT LIVER CANCER study is
evaluating TTI-101 as monotherapy and in combination with established
therapies in patients with HCC. The Company expects to report topline
data early in the first quarter of 2027 to allow for complete cohort
evaluation.
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, "We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps."
Key Upcoming Milestones
-- 2027: Initiation of clinical trial of TTI-109 in UC, subject to IND
clearance and additional funding
-- Early first quarter of 2027: TTI-101 Phase 1b/2 HCC topline data
Third Quarter 2026 Financial Results
Research and development expenses for the three months ended September 30, 2026, were $4.5 million, compared to $3.6 million for the comparable period in 2025. The increase was primarily driven by higher clinical costs associated with TTI-101.
General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.3 million for the three months ended September 30, 2025. The decrease was primarily driven by lower professional fees.
Net loss for the three months ended September 30, 2026, was $6.1 million, compared to a net loss of $5.5 million for the three months ended September 30, 2025.
Basic and diluted net loss per share attributable to common stockholders for the three months ended September 30, 2026, were both $(0.48), compared to basic and diluted net loss per share of $(0.59) for the three months ended September 30, 2025.
Cash and cash equivalents as of September 30, 2026, were $22.3 million, compared to cash, cash equivalents and short-term investments of $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027. Advancing TTI-109 into UC and additional indications remain subject to additional funding and IND clearance.
About Tvardi Therapeutics
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in ulcerative colitis pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).
Cautionary Statement Regarding Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the anticipated bene ts of Tvardi's product candidates; its ongoing clinical trials and anticipated timing of reporting data from such trials; potential indications for its product candidates; its anticipated cash runway; and other statements regarding management's intentions, plans, beliefs, expectations or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are subject to a number of risks, including, among other things: the uncertainties associated with Tvardi's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials or safety or other complications related to its product candidates; the ability to obtain IND clearance for TTI-109 in UC on the timelines expected or at all; the ability to replicate results for preclinical studies and early clinical trials in later trials; the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; the signi cant net losses Tvardi has incurred since inception; Tvardi's ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance its product candidates through clinical development; the timing of the availability of data from Tvardi's clinical trials; the outcome of preclinical testing and clinical trials of Tvardi's product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; Tvardi's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential bene ts and market acceptance of Tvardi's product candidates; Tvardi's anticipated cash runway; Tvardi's ability to attract, hire, and retain skilled executive officers and employees; Tvardi's ability to protect its intellectual property and proprietary technologies; Tvardi's reliance on third parties, contract manufacturers, and contract research organizations; the possibility that Tvardi may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; those factors discussed in Tvardi's lings with the Securities and Exchange Commission, including the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2025, and Tvardi's other documents subsequently led with or furnished to the SEC, all of which are available on the SEC's website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to re ect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Contacts:
For Tvardi:
Tvardi Investor Relations
ir@tvardi.com
PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com
TVARDI THERAPEUTICS
Consolidated Balance Sheets
(Unaudited, amounts in thousands, except share and
per share amounts)
As of September 30, As of December 31,
--------------------- ----------------------
2026 2025
--------------------- ----------------------
Assets
Current assets:
Cash and cash
equivalents $ 22,275 $ 20,734
Short-term
investments -- 10,077
Prepaid expenses
and other current
assets 855 727
---------------- ---------------
Total current assets 23,130 31,538
Property and equipment,
net 28 52
Intangible assets, net 275 322
Operating lease
right-of-use assets 83 144
Other non-current assets 17 17
---------------- ---------------
Total assets $ 23,533 $ 32,073
================ ===============
Liabilities and
Stockholders' Equity
Current liabilities:
Accounts payable $ 2,076 $ 3,219
Accrued expenses 5,885 7,707
Operating lease
liabilities, current
portion 116 116
---------------- ---------------
Total current
liabilities 8,077 11,042
Operating lease
liabilities, net of
current portion -- 85
---------------- ---------------
Total liabilities 8,077 11,127
Stockholders' Equity:
Common stock, $0.001
par value;
150,000,000 shares
authorized as of
September 30, 2026
and December 31,
2025; 13,345,956
shares and 9,381,344
shares issued and
outstanding as of
September 30, 2026
and December 31,
2025, respectively 13 9
Additional paid-in
capital 145,278 131,379
Accumulated other
comprehensive
income -- 8
Accumulated deficit (129,835) (110,450)
---------------- ---------------
Total stockholders'
equity 15,456 20,946
---------------- ---------------
Total liabilities
and stockholders'
equity $ 23,533 $ 32,073
================ ===============
TVARDI THERAPEUTICS
Consolidated Statements of Operations
(Unaudited, amounts in thousands, except share and
per share amounts)
For the Three Months For the Nine Months Ended
Ended September 30, September 30,
------------------------- ---------------------------
2026 2025 2026 2025
------------ ----------- ------------ -------------
Operating
expenses:
Research and
development $ 4,474 $ 3,603 $ 13,387 $ 12,520
General and
administrative 1,854 2,335 6,621 6,641
---------- --------- ---------- ---------
Total
operating
expenses 6,328 5,938 20,008 19,161
---------- --------- ---------- ---------
Loss from
operations (6,328) (5,938) (20,008) (19,161)
Interest income 204 411 623 1,063
Other income, net -- -- -- 7,159
---------- --------- ---------- ---------
Net loss $ (6,124) $ (5,527) $ (19,385) $ (10,939)
========== ========= ========== =========
Net loss per
share
attributable to
common
stockholders:
Basic $ (0.48) $ (0.59) $ (1.85) $ (1.62)
========== ========= ========== =========
Diluted $ (0.48) $ (0.59) $ (1.85) $ (2.50)
========== ========= ========== =========
Weighted-average
common shares
outstanding:
Basic 12,653,836 9,377,079 10,484,162 6,757,955
========== ========= ========== =========
Diluted 12,653,836 9,377,079 10,484,162 7,244,785
========== ========= ========== =========
Comprehensive
loss:
Net loss $ (6,124) $ (5,527) $ (19,385) $ (10,939)
Unrealized
(loss) gain on
short-term
investments -- 20 (8) 7
---------- --------- ---------- ---------
Comprehensive loss $ (6,124) $ (5,507) $ (19,393) $ (10,932)
========== ========= ========== =========
Comments